Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy

Blood Transfusion

Volumn 12, Issue 4, 2014, Pages 575-598

  Rocino, Angiola ^a   Coppola, Antonio ^b   Franchini, Massimo ^c   Castaman, Giancarlo ^d,e   Santoro, Cristina ^f   Zanon, Ezio ^g   Santagostino, Elena ^h   Morfini, Massimo ⁱ   Accorsi, Arianna ^j   Brigida Aru, Anna ^j   Biasoli, Chiara ^j   Cantori, Isabella ^j   Cesaro, Simone ^j   Ciabatta, Carlo ^j   De Cristofaro, Raimondo ^j   Delios, Grazia ^j   Di Minno, Giovanni ^j   D'Incà, Marco ^j   Dragani, Alfredo ^j   Pietro Ettorre, Cosimo ^j   Gagliano, Fabio ^j   Gamba, Gabriella ^j   Gandini, Giorgio ^j   Giordano, Paola ^j   Giuffrida, Gaetano ^j   Gresele, Paolo ^j   Jane Hassan, Hamisa ^j   Latella, Caterina ^j   Luciani, Matteo ^j   Margaglione, Maurizio ^j   Marietta, Marco ^j   Gabriella Mazzucconi, Maria ^j   Messina, Maria ^j   Claudio Molinari, Angelo ^j   Dora Notarangelo, Lucia ^j   Peyvandi, Flora ^j   Piseddu, Gavino ^j   Rossetti, Gina ^j   Rossi, Vincenza ^j   Carlotta Santoro, Rita ^j   Schiavoni, Mario ^k   Schinco, Piercarla ^j   Luisa Serino, Maria ^j   Tagliaferri, Annarita ^j   Testa, Sophie ^j   more..

^a San Giovanni Bosco Hospital   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ Italian Association of Haemophilia Centres (AICE)   (Italy)

^j NONE   (Italy)

^k NONE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; DESMOPRESSIN; FIBRIN GLUE; TRANEXAMIC ACID;

ARTICLE; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; CONGENITAL BLEEDING DISORDER; CONGENITAL BLOOD CLOTTING DISORDER; FIBRINOGEN DEFECT; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; ITALY; PATHOGENESIS; PATIENT PREFERENCE; PATIENT SAFETY; PROTHROMBIN DEFICIENCY; THROMBOGENICITY; VACCINATION; VITAMIN K DEFICIENCY; VON WILLEBRAND DISEASE; BLOOD; FEMALE; GENETICS; MALE; PATHOLOGY; PRACTICE GUIDELINE;

FEMALE; HEMOPHILIA A; HUMANS; ITALY; MALE;

EID: 84908672673     PISSN: 17232007     EISSN: 23852070     Source Type: Journal    
DOI: 10.2450/2014.0223-14     Document Type: Article

References (198)

1. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
2. Teitel JM, Barnard D, Israels S, et al. Home management of haemophilia. Haemophilia 2004; 10: 118-33.
3. Strawczynski H, Stachewitsch A, Morgenstern G, Shaw ME. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1975; 51: 986-91.
4. Accordo Stato-Regioni sulla "Definizione dei percorsi regionali o interregionali di assistenza per le persone affette da Malattie Emoragiche Congenite (MEC)", 13 March 2013. GU n.107 of 9-5-2013.
5. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27: 179-84.
6. Peyvandi F, Garagiola I, Seregni S. Future of factor replacement treatment. J Thromb Haemost 2013; 11 (Suppl 1): 84-98.
7. Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
8. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
9. Colvin BT, Astermark J, Fischer K, et al; Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
10. Franchini M, Coppola A, Rocino A, et al; on behalf the Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost 2013; 39: 752-66.
11. Franchini M, Coppola A, Rocino A, et al; the Italian Association of Hemophilia Centers (AICE) Working Group. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters. The 2013 AICE survey. Haemophilia 2014; 20: e128-35.
12. Brooker M. Registry of clotting factor concentrates. World Federation of Hemophilia, Montreal, QC, Canada, 9th edition, 2012. Available at: http://www.wfh.org. Accessed on 01/09/2014.
13. Clotting factor products directory. European Haemophilia Safety Surveillance. http://www.euhass.org. Accessed on: 01/09/2014.
14. Fletcher ML, Trowell JM, Craske J et al. Non-A, non-B hepatitis after transfusion of factor VIII in unfrequently treated patients. Br Med J 1983; 287: 1754-7.
15. Kernoff PBA, Lee CA, Karayanis P, Thomas HC. High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60: 469-79.
16. Gringeri A, Mannucci PM. National survey of human immunodeficiency virus infection in Italian hemophiliacs: 1983-1987. The Medical-Scientific Committee of the Fondazione dell'Emofilia. Ric Clin Lab 1988; 18: 275-80.
17. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-8.
18. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010; 8: 288-91.
19. Centers for Disease Control and Prevention (CDC). Blood safety monitoring among persons with bleeding disorders- United States, May 1998-June 2002. MMWR Morb Mortal Wkly Rep 2003; 51: 1152-4.
20. Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 (Suppl 2): S22-5.
21. Council of Europe. Commission Directive 2003/63/EC. Community code relating to medicinal products for human use. Official Journal of European Union, 27 June 2003. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/dir-2003-63/dir-2003-63-en.pdf. Accessed on 01/09/2014.
22. Franchini M. The modern treatment of hemophilia. Blood Transfus 2013; 11: 178-82.
23. Franchini M, Lippi G. Recombinant FVIII products. Semin Thromb Hemost 2010; 36: 537-49.
24. Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001; 98: 2571-3.
25. Ludlam CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006; 367: 252-61.
26. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. Semin Thromb Haemost 2013; 39: 779-93.
27. Soucie JM, De Staercke C, Monahan PE, et al; US Hemophilia Treatment Center Network. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion 2013; 53: 1217-25.
28. European Medicines Agency (EMEA). Press release. Supply shortages of Cerezyme and Fabrazyme- priority access for patients most in need of treatment recommended. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2009/11/news-detail-000075.jsp. Accessed on 01/09/2014.
29. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
30. Zaman SM, Hill FG, Palmer B, et al. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia 2011; 17: 931-7.
31. Brown P, Cervenakova L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
32. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang 2005; 89: 63-70.
33. UK Haemophilia Centre Doctors' Organization. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
34. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
35. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
36. Belvini D, Salviato R, Radossi P, et al; AICE HB Study Group. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005; 90: 635-42.
37. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-15.
38. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
39. Hay CR, Palmer B, Chalmers E, et al; United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
40. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16: 66-70.
41. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
42. Astermark J, Voorberg J, Lenk H, et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
43. Delignat S, Dasgupta S, André S, et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007; 92: 1423-6.
44. Goudemand J, Rothschild C, Demiguel V, et al; FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
45. Gouw SC, van der Bom JG, Auerswald G, et al.; for the CANAL Study group. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
46. Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10: 781-90.
47. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
48. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012; 81: 82-93.
49. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl 5): 65-8.
50. Fischer K, Makris M, Calizzani G, et al. European monitoring of inhibitor development in hemophilia A and B. Oral Communication (OC 22.2) XXIV ISTH Congress, Amsterdam 2013.
51. Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
52. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood 2013; 122: 636-40.
53. White GC, DiMichele D, Mertens K, et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs) and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee of Factor VIII and Factor IX of the Scientific and Standardization Committte of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
54. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A metaanalysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-92.
55. Xi M, Makris M, Marcucci M, et al. Inhibitor development in previously treated Haemophilia A patients: a systematic review, meta-analysis and meta-regression. J Thromb Haemost 2013; 11: 1655-62.
56. Rubinger M, Lillicrap D, Rivard GE, et al; Association of Hemophilia Clinic Directors of Canada. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-6.
57. Rea C, Dunkerley A, Sørensen B, Rangarajan S. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII. Haemophilia 2009; 15: 1237-42.
58. Bacon CL, Singleton E, Brady B, et al. Low risk of inhibitor formation in haemophilia a patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE). Haemophilia 2011; 17: 407-11.
59. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
60. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41 (Suppl 1): 101-8.
61. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus FVIII bypassing activity. J Thromb Haemost 2004; 2: 1700-8.
62. Scharrer I. The need for highly purified products to treat haemophilia B. Acta Haematologica 1995; 94: 2-7.
63. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62: 1614-22.
64. Mannucci PM, Bauer KA, Gringeri A, et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-5.
65. Hampton KK, Preston FE, Lowe GD, et al. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279-84.
66. Coppola A, Franchini M, Makris M, et al. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173-87.
67. Smith JK. Factor XI and its management. Haemophilia 1996; 2: 128-36.
68. Bornikova L, Peyvandi F, Allen G, et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9: 1687-704.
69. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39: 585-95.
70. Abshire T. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. Semin Hematol 2008; 45 (2 Suppl 1): S3-6.
71. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39-43.
72. Mannucci PM, Franchini M, Castaman G, Federici AB; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
73. Makris M, Conlon CP, Watson HG. Immunization of patients with bleeding disorders. Haemophilia. 2003; 9: 541-6.
74. Steele M, Cochrane A, Wakefield C, et al. Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia. 2009; 15: 437-47.
75. Mannucci PM, Gringeri A, Santagostino E, Peyvandi F. Factor VIII inhibitor and source of replacement therapy. Blood Transfus 2012; 10: 112-3.
76. Astermark J, Morado M, Rocino A, et al; European Haemophilia Treatment Standardisation Board (EHTSB). Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
77. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl 1): 1-22.
78. Collins PW, Chalmers E, Hart DP, et al; UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160 :153-70.
79. Committee for Medicinal Products for Human USE (CHMP). Reflection paper on immune tolerance induction in haemophilia A patients with inhibitors. EMA/CHMP/ BPWP/153137/2011 (21 march 2013).
80. Determina AIFA 208/2014, 06.03.2014, G.U. Serie Generale n. 72 del 27.03.2014, 36.
81. Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with highresponding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
82. Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
83. Young G, Auerswald G, Jimenez-Yuste V, et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012; 130: 864-70.
84. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
85. Hoots WK, Ebbesen LS, Konkle BA, et al; Novoseven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
86. Young G, Auerswald G, Jimenez-Yuste V, et al. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 17: e849-57.
87. Wolf DM, Rokicka-Milewska R, Lopaciuk S, et al. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. Haemophilia 2004; 10: 438-48.
88. Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of followup. Haemophilia 2007; 13: 697-700.
89. Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res 2011; 127: 247-53.
90. Nemes L, Pollmann H, Becker T. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A. Haemophilia 2012; 18: 496-502.
91. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
92. Musso R, Santagostino E, Faradji A, et al; Kogenate Bayer European PMS Study Group. Safety and efficacy of sucroseformulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-8.
93. Blanchette VS, Shapiro AD, Liesner RJ, et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
94. Lusher JM, Lee CA, Kessler CM, Bedrosian CL; ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
95. Warrier I, Kasper CK, White GC 2nd, et al. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. Am J Hematol 1995; 49: 92-4.
96. Lissitchkov T, Matysiak M, Zawilska K, et al. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2010; 16: 240-6.
97. Lissitchkov T, Matysiak M, Zavilska K, et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®), a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2011; 17: 590-6.
98. Serban M, Skotnicki AB, Colovic M, et al. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. Haemophilia 2012; 18: 175-81.
99. Roth DA, Kessler CM, Pasi KJ, et al; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
100. Calizzani G, Arcieri R. Clinical and organisational aspects of haemophilia care: the patients' view. Blood Transfus 2012; 10: 110-1.
101. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 2013; 98: 1495-8.
102. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1977; i: 869-72.
103. Seary ME, Feldman D, Carcao MD. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype. Haemophilia 2012; 18: 50-5.
104. Miesbach W, Krekeler S, Dück O, et al. Clinical assessment of efficacy and safety of DDAVP. Hamostaseologie 2010; 30 (Suppl 1): S172-5.
105. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
106. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202.
107. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
108. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.
109. Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica 2010; 95: 963-9.
110. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 2012; 18: 25-33.
111. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53.
112. Sindet-Pedersen S, Stenbjerg S. Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg 1986; 44: 703-7.
113. Franchini M, Rossetti G, Tagliaferri A, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11: 504-9.
114. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
115. Holmström M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A-a two-centre experience. Haemophilia 2012; 18: 544-9.
116. van Itterbeek H, Vermylen J, Verstraete M. High obstruction of urine flow as a complication of the treatment with fibrinolysis inhibitors of haematuria in haemophiliacs. Acta Haematol 1968; 39: 237-42.
117. Forbes CD, Prentice CR. Renal disorders in haemophilia A and B. Scand J Haematol Suppl 1977; 30: 43-50.
118. Martinowitz U, Schulman S. Fibrin sealant in surgery of patients with a haemorrhagic diathesis. Thromb Haemost 1995; 74: 486-92.
119. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 (Suppl 4): 13-23.
120. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
121. Nilsson IM, Berntorp E, Loqvist T, Petterson H. Twentyfive years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
122. Aledort LM, Haschmeyer RH, Petterson H, Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
123. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
124. Gringeri A, Lundin B, Mackensen SV, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
125. Petrini P. How to start prophylaxis. Haemophilia 2003; 9 (Suppl 1): 83-5.
126. Feldman BM, Pai M, Rivard GE, et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
127. Fischer K, Van Der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
128. Richards M, Altisent C, Batorova A, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? A European survey of practice and outcome data. Haemophilia 2007; 13: 473-9.
129. Manco-Johnson MJ, Sanders J, Ewing N, et al; TEEN/TWEN Study Group. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia 2013; 19: 727-35.
130. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
131. Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
132. Valentino LA, Mamonov V, Hellmann A, et al; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
133. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
134. Tagliaferri A, Rivolta GF, Coppola A, et al. Prophylaxis versus on-demand therapy through economic report (POTTER) study: preliminary data from the final five-year analysis. Haemophilia 2012; 18 (Suppl 3): 160.
135. Gringeri A, Mannucci PM; Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
136. Astermark J, Rocino A, Von Depka M, et al; EHTSB. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
137. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
138. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors. A systematic review. Haemophilia 2003; 9: 436-63.
139. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
140. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
141. Mariani G, Kroner B, for the Immune Tolerance Study Group. Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
142. DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-8.
143. Hay CR, Dimichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
144. Coppola A, Mancuso ME, Linari S, et al. Induzione di immunotolleranza in emofilici A con inibitore high-responding: regimi di trattamento e risultati nei bambini e negli adulti. Blood Transfus 2011; 9 (Suppl 6): s54-5.
145. Rocino A, Papa, ML, Salerno E, et al. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001; 7: 33-8.
146. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558-61.
147. Lenk H. The German registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85: 45-7.
148. Kreuz W, Escuriola-Ettingshausen C, Auerswald G, et al. Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica 2001; 86 (Suppl 4): 16-20.
149. Gringeri A, Musso R, Mazzucconi MG, et al; RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
150. Kurth M, Puetz M, Kouides P, et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9: 2229-3.
151. Barnes C, Rivard GE, Poon M-C, et al. Canadian multiinstitutional survey of immune tolerance therapy (ITT)- experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12: 1-6.
152. Rivard GE, Rothschild C, Toll T, Achilles K. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Haemophilia 2013; 19: 449-55.
153. Collins PW, Mathias M, Hanley J, et al; UK Haemophilia Centre Doctors' Organisation. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009; 7: 787-94.
154. Negrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of hemophilia complicated by an inhibitor. Haemophilia 2006; 12 (Suppl 5): 4-13.
155. Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. Bio Drugs 2008; 22: 121-36.
156. Jiménez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, et al. Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors. Semin Hematol 2008; 45 (2 Suppl 1): S64-7.
157. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 1-5.
158. Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39: 772-8.
159. Váradi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10 (Suppl 2): 17-21.
160. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12 (Suppl 6): 48-52.
161. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-71.
162. Escuriola-Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010; 16: 90-100.
163. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
164. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2013; 20: 65-72.
165. Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43.
166. Gomperts ED. FEIBA safety and tolerability profile. Haemophilia 2006; 12 (Suppl 5): 14-9.
167. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
168. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-31.
169. Castaman G, Bonetti E, Messina M, et al; Italian Association of Hemophilia Centers. Inhibitors in haemophilia B: the Italian experience. Haemophilia 2013; 19: 686-90.
170. D'Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008; 14 (Suppl 3): 138-46.
171. Mauser-Bunschoten EP, Den Ujil IE, Schutgens RE, et al. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 2012; 18: 263-7.
172. Eckhardt CL, van Velzen AS, Peters M, et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954-62.
173. Eckhardt CL, Menke LA, Van Ommen CH et al. Intensive perioperative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
174. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
175. Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica 2013; 98: 667-74.
176. Federici AB, Bucciarelli P, Castaman G, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37: 511-21.
177. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/ removal methods. J Thromb Haemost 2005; 3: 2219-27.
178. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coag Fibrinol 2005; 16 (Suppl 1): S23-6.
179. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease. The PRO. WILL study. Haemophilia 2007; 13 (Suppl 5): 15-24.
180. Abshire TC, Federici AB, Alvarez MT, et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand disease prophylaxis network (VWD PN). Haemophilia 2013; 19: 76-81.
181. D.M.03/03/2005: "Caratteristiche e modalità per la donazione del sangue e di emocomponenti" pubblicato in G.U. Serie Generale, n. 85 of 13 April 2005.
182. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4: 1634-7.
183. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
184. Castaman G, Lunardi M, Rigo L, et al. Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo- and afibrinogenemia. Haemophilia 2009; 15: 533-7.
185. Auerswald G. Prophylaxis in rare coagulation disorders-factor X deficiency. Thromb Res 2006; 118 (Suppl 1): S29-31.
186. Cohen LJ, McWilliams NB, Neuberg R, et al. Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports. Am J Hematol 1995; 50: 269-76.
187. Napolitano M, Giansily-Blaizot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013; 98: 538-44.
188. Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-3.
189. Salomon O, Steinberg DM, Tamarin I, et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinol 2005; 16: 37-41.
190. Castaman G, Ruggeri M, Rodeghiero F. Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symtomatic heterolygous factor XI defieciency. Br J Haematol 1996; 94: 168-70.
191. Berliner S, Horowitz I, Martinowitz U, et al. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coag Fibrinol 1992; 3: 465-468.
192. Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-8.
193. Zadra G, Asselta R, Tenchini ML, et al. Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica 2008; 93: 715-21.
194. Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102: 487-92.
195. Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia 2013; 19: e349-57.
196. Zheng C, Liu HH, Yuan S, et al. Molecular basis of LMAN1 in coordinating LMAN1-MCFD2 cargo receptor formation and ER-to-Golgi transport of FV/FVIII. Blood 2010; 116: 5698-706.
197. Zheng C, Zhang B. Combined deficiency of coagulation factors V and VIII: an update. Semin Thromb Hemost 2013; 39: 613-20.
198. Napolitano M, Mariani G, Lapecorella M. Hereditary combined deficiency of the vitamin K-dependent clotting factors. Orphanet J Rare Dis 2010; 5: 21.